MedPath

The effect of magnesium sulfate on recurrence of rebound pain in patients undergoing regional anesthesia in the arm

Not Applicable
Conditions
Prevention of rebound pain in patients undergoing supraclavicular brachial plexus block for upper limb surgery.
Surgery
Registration Number
ISRCTN11083070
Lead Sponsor
The Committee for Ethics in Research (CEP) in ABC's Foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
All
Target Recruitment
34
Inclusion Criteria

1. Patients with ASA Physical Status classification I-lll;
2. Ability to understand and complete the pain diary;
3. Patients undergoing arm, forearm and hand surgery with indication for supraclavicular brachial plexus block without the association of another regional block or general anesthesia.

Exclusion Criteria

1. Severe heart disease;
2. Decompensated kidney disease;
3. Decompensated liver disease;
4. Severe respiratory failure;
5. Cognitive dysfunction that prevents cooperation with the study;
6. Calcium channel blocker treatment;
7. Confirmed coagulopathy;
8. Infection at the procedure location;
9. Illicit drug used 5 days ago;
10. Daily use of opioids more than 14 days before surgery;
11. Block failure;
12. Need to send to the intensive care unit (ICU) in the immediate postoperative period;
13. Neuropathy in the upper limb to be operated;
14. Allergy to local anesthetic, propofol or non-steroidal anti-inflammatory drugs;
15. Weight <50 Kilograms (kg);
16. Body mass index (BMI) > 35 kg/m²;
17. Chronic pain;
18. Pregnancy;
19. Need to change the anesthetic technique intraoperatively.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> 1. Pain measured by the Visual Numerical Scale (VNS) every 6 hours after the block for 24 hours<br> 2. The time of block resolution, considered as the time when the first rescue analgesia was taken. However, in cases that didn’t require rescue analgesia, the time of block resolution will be considered when the patient reports the end of numbness or the end of heaviness in the blocked region.<br>
Secondary Outcome Measures
NameTimeMethod
Average cumulative opioid consumption in milligrams between the groups in the first 24 hours after the block, according to the doses taken and checked in the medical prescription.
© Copyright 2025. All Rights Reserved by MedPath